What jCyte does

jCyte is a clinical-stage biotechnology company developing jCell (famzeretcel), a first-in-class allogeneic retinal progenitor cell (RPC) therapy for retinitis pigmentosa (RP) and other degenerative retinal disorders. Co-founded by Dr. Henry Klassen and Dr. Jing Yang and headquartered in Newport Beach, California, jCyte's lead candidate is administered as a single intravitreal injection designed to release neurotrophic factors that protect and restore surviving photoreceptors. Unlike gene therapy approaches that require patient-specific genetic matching, jCell is off-the-shelf and genotype-agnostic, allowing treatment across all genetic subtypes of RP—an addressable population of approximately 2 million patients worldwide (~100,000 in the U.S.) for whom there are no FDA-approved disease-modifying therapies.

The company's core technology is supported by a proprietary manufacturing process developed jointly with Center for Breakthrough Medicines (CBM) for Phase 3 trial supply and commercial-scale GMP production. jCell has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation from both the FDA and EMA. jCyte is currently advancing the JC02-88 Phase 2 trial (first patients dosed August 2025) evaluating a higher 8.8 million-cell dose in up to 60 RP patients, building toward a planned Phase 2/3 pivotal study following the FDA's January 2024 pre-Phase 3 Type B meeting. The company also maintains preclinical programs in diabetic retinopathy and optic nerve diseases, demonstrating pipeline expansion beyond the RP indication.

jCyte operates a dual commercial model: it retains U.S. commercialization rights and plans a direct launch through a specialty ophthalmology sales force, while Santen Pharmaceutical holds ex-U.S. rights (Europe and Asia) under a May 2020 licensing agreement valued at up to $252 million ($50M upfront cash, $12M convertible note, up to $190M in milestones, plus tiered double-digit royalties on net sales). The company has been funded primarily through non-dilutive California Institute for Regenerative Medicine (CIRM) grants totaling over $30 million and remains pre-revenue, with future revenue contingent on FDA BLA approval and subsequent commercialization in the U.S. and partner territories.

Name

jCyte

Legal name

jCyte, Inc.

Website

https://jcyte.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

jCyte is a clinical-stage biotechnology company developing jCell, a first-in-class allogeneic retinal progenitor cell therapy as an investigational treatment for retinitis pigmentosa and other degenerative retinal disorders currently in Phase 2 clinical trials.

Ownership category

akta.pro rank

Product category

Ophthalmic Cell Therapy / Retinal Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Ophthalmology Disorder Therapies (HLAIAIAK)

akta.pro secondary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Retinal cell therapy
• Regenerative medicine
• Ophthalmic biologics
• Clinical-stage biotechnology
• Cell-based therapeutics

Headquarters

HQ city

Newport Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Ex-U.S. Licensing Royalties (Santen): jCyte receives tiered, double-digit royalty payments on net commercial sales of jCell therapy in Europe and Asia under the 2020 licensing agreement with Santen Pharmaceutical. Royalties are payable upon commercialization in Santen's licensed regions.
2. Ex-U.S. Milestone Payments (Santen): jCyte is entitled to receive up to $190 million in clinical and sales milestone payments contingent on regulatory approval and initial commercial sales of jCell in Europe and Asia under the 2020 licensing agreement.
3. U.S. Product Sales (Post-Approval): Upon BLA approval and commercialization of jCell in the United States, jCyte intends to generate revenue through direct product sales of jCell to hospitals, ambulatory surgical centers, and ophthalmology clinics. U.S. commercialization will be managed by the company's own commercial infrastructure.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

jCyte is a clinical-stage biotechnology company developing jCell (famzeretcel), a first-in-class allogeneic human retinal progenitor cell (hRPC) therapy administered as a single minimally invasive intravitreal injection for the treatment of retinitis pigmentosa (RP). The therapy works through sustained release of neurotrophic factors that reduce photoreceptor cell death and promote function of surviving cone and rod photoreceptors, and is genotype-agnostic across all RP genetic subtypes. The company is currently advancing the JC02-88 Phase 2 trial and plans to pursue BLA approval for direct U.S. commercialization while earning royalties from its Santen Pharmaceutical ex-U.S. licensing partnership.

Product overview

jCyte is a clinical-stage biotech company developing jCell (famzeretcel), a first-in-class allogeneic cell therapy for retinitis pigmentosa and other degenerative retinal disorders. The lead product jCell is administered as a minimally invasive intravitreal injection and works by releasing neurotrophic factors to protect and restore photoreceptor function. The company is advancing JC02-88, a Phase 2 clinical trial, while also pursuing preclinical programs in diabetic retinopathy and optic nerve diseases. jCell has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation from both FDA and EMA, positioning it for an expedited regulatory pathway.

Differentiator

Problem solved

Functional benefit

Products and services

• jCell (famzeretcel) First-in-class allogeneic human retinal progenitor cell (hRPC) therapy administered as a single, minimally invasive intravitreal injection for the treatment of retinitis pigmentosa (RP). The therapy works through sustained release of neurotrophic factors that reduce photoreceptor cell death and promote function of surviving cone and rod photoreceptors, and is genotype-agnostic across all RP genetic subtypes.
• JC02-88 Clinical Trial (8.8M cell dose pivotal trial) Phase 2 clinical trial evaluating the safety and efficacy of a single 8.8 million cell intravitreal injection of jCell in approximately 60 RP patients aged 18–60 with any genetic subtype, BCVA 20/80–20/800, and central visual field diameter ≥8°, conducted at approximately 15 U.S. clinical trial sites with the UC Irvine Gavin Herbert Eye Institute as the central testing facility.
• Diabetic Retinopathy Program Preclinical pipeline program investigating intravitreal human retinal progenitor cell transplantation for diabetic retinopathy, with cross-species efficacy (improved ERG b-wave, oscillatory potentials, optomotor response, contrast sensitivity; reduced VEGF expression and albumin extravasation) demonstrated in a rat model using human RPCs.
• Optic Nerve Disease Program Research program exploring use of jCyte's allogeneic retinal progenitor cell platform for glaucoma and other optic nerve diseases.

Quantifiable outcome

• Phase 2b: +16.27 letter improvement in BCVA vs. +1.85 for sham at 12 months (p=0.003) in target population receiving 6M cell dose
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core / flagship and minor.

• Center for Breakthrough Medicines (CBM)core / flagshipTechnology or Integration · 20 September 2022jCyte entered into a multi-year manufacturing agreement with Center for Breakthrough Medicines (CBM), a purpose-built cell and gene therapy CDMO based in Philadelphia's Cellicon Valley. CBM serves as the primary manufacturer of jCell for Phase 3 clinical trial supplies and commercial drug product following BLA approval. CBM also provides all BLA-enabling CMC work to support regulatory approval and commercialization. CBM offers fully dedicated manufacturing suites and analytical testing services tailored to jCyte's proprietary manufacturing process.
• Santen Pharmaceutical Co., Ltd.core / flagshipOEM/ Whitelabel/ Licensing Partner · 8 May 2020jCyte entered into an ex-U.S. licensing and commercialization agreement with Santen Pharmaceutical for jCell therapy. Under the terms, jCyte received $50M upfront cash, $12M in a convertible note offering, and up to $190M in clinical and sales milestones based on regulatory approval and initial sales in Europe and Asia. jCyte is also entitled to tiered, double-digit royalty payments on net commercial sales. Santen gains exclusive rights to develop and commercialize jCell in all regions outside the U.S. The agreement leverages Santen's extensive global ophthalmology sales network, capabilities, and infrastructure covering over 60 countries.
• Gavin Herbert Eye Institute, UC Irvinecore / flagshipStrategic or Co-development PartnerThe Gavin Herbert Eye Institute at UC Irvine is a key strategic partner, serving as the primary treatment and manufacturing site for JC02-88 trial patients and providing GMP manufacturing capabilities through the UCI GMP Facility. The institute is led by Dr. Baruch Kuppermann (SAB member and department chair) and Dr. Henry Klassen (co-founder of jCyte). jCyte originated as a UCI startup company. The institute provides the central testing facility and primary clinical infrastructure for jCyte's pivotal trials.
• Lexitas (Clinical Research Organization)minorImplementation/ SI/ Consulting PartnerLexitas is a specialized clinical research organization with over 14 years dedicated exclusively to ophthalmology. Lexitas is a key partner supporting the JC02-88 clinical trial, providing clinical research services across the trial's network of approximately 15 U.S. clinical sites.
• Foundation Fighting BlindnessminorGTM or Marketing PartnerFoundation Fighting Blindness is a patient advocacy organization that has featured jCyte's clinical trial results and future plans in its communications to the RP patient community. The organization publishes podcasts (Eye on the Cure), research updates, and clinical trial announcements to help connect patients with experimental treatments under development.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• MeiraGTx: Clinical-stage gene therapy company developing treatments for inherited retinal diseases including retinitis pigmentosa and other ocular conditions. Directly comparable to jCyte in targeting RP and ophthalmology, though using AAV gene therapy rather than cell therapy.
• 4D Molecular Therapeutics: Clinical-stage genetic medicines company with multiple ophthalmology programs including treatments for inherited retinal diseases like RP and choroideremia. Comparable as a late-stage ophthalmology therapeutic developer with similar patient population and regulatory pathway.
• GenSight Biologics: Clinical-stage biopharma developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Comparable as a developer of ophthalmology-targeted genetic/cell-based therapies for rare inherited blindness conditions.
• ProQR Therapeutics: Late-stage clinical biotech developing RNA editing therapies for inherited retinal diseases including retinitis pigmentosa (e.g., ultevursen for USH2A-related RP). Directly comparable as an RP-focused therapeutic developer using a different modality.

Broad incumbents

• REGENXBIO: Clinical-stage gene therapy company with a leading AAV delivery platform used in multiple ophthalmology programs, including partnerships for retinal diseases. Comparable as a broader ocular gene therapy platform developer with deeper resources than jCyte.
• Spark Therapeutics (Roche): Fully integrated gene therapy company (acquired by Roche) that developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited retinal disease (RPE65 mutation). Comparable as the established leader in retinal gene therapy and a benchmark for RP therapeutic commercialization.
• Biogen (Nightstar Therapeutics acquisition): Large biopharma that acquired Nightstar Therapeutics in 2019 to enter the retinal gene therapy space (including RP programs). Comparable as a major player in the inherited retinal disease therapeutic space through prior M&A.

Emerging players

• Coave Therapeutics: Clinical-stage genetic medicines company developing AAV-based gene therapies for ocular and CNS diseases, including retinitis pigmentosa. Comparable as a smaller, emerging retinal gene therapy developer pursuing similar indications with a different modality.
• Editas Medicine: Clinical-stage CRISPR genome editing company with an ophthalmology program targeting inherited retinal diseases including Leber congenital amaurosis. Comparable as an emerging ocular therapeutic developer using gene editing/cell therapy approaches for rare blindness conditions.
• Endogena Therapeutics: Clinical-stage biotech developing regenerative cell and small molecule therapies for degenerative eye diseases including retinitis pigmentosa and glaucoma. Closely comparable to jCyte as a cell-based therapy developer for retinal degenerative disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/j_cyte

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about jCyte